Trial Profile

A phase 3b trial of NCX 470

Status: Not yet recruiting

Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bimatoprost-grenod (Primary)
Indications Ocular hypertension; Open-angle glaucoma
Focus Pharmacodynamics
Sponsors NicOx

Most Recent Events

27 May 2025 According to a Nicox media release, the company announced up to 3 million euro in milestone payments from Kowa in 2025 as NCX 470 prepares to enter phase 3 clinical trials in Japan.
27 May 2025 According to a Nicox media release, this trial expected to be initiated in H2 2025, which would trigger a second milestone payment of 2 million euro.
27 May 2025 According to a Nicox media release, exclusive Japanese partner Kowa has received regulatory approval to initiate Phase 3 clinical trials on NCX 470 for the treatment of ocular hypertension in Japan.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com